These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 12359877)
1. On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines. Ragupathi G; Coltart DM; Williams LJ; Koide F; Kagan E; Allen J; Harris C; Glunz PW; Livingston PO; Danishefsky SJ Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13699-704. PubMed ID: 12359877 [TBL] [Abstract][Full Text] [Related]
2. Prospects for total synthesis: a vision for a totally synthetic vaccine targeting epithelial tumors. Keding SJ; Danishefsky SJ Proc Natl Acad Sci U S A; 2004 Aug; 101(33):11937-42. PubMed ID: 15280546 [TBL] [Abstract][Full Text] [Related]
3. Constructing an adenocarcinoma vaccine: immunization of mice with synthetic KH-1 nonasaccharide stimulates anti-KH-1 and anti-Le(y) antibodies. Ragupathi G; Deshpande PP; Coltart DM; Kim HM; Williams LJ; Danishefsky SJ; Livingston PO Int J Cancer; 2002 May; 99(2):207-12. PubMed ID: 11979435 [TBL] [Abstract][Full Text] [Related]
4. Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice. Kudryashov V; Glunz PW; Williams LJ; Hintermann S; Danishefsky SJ; Lloyd KO Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3264-9. PubMed ID: 11248067 [TBL] [Abstract][Full Text] [Related]
5. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers. Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527 [TBL] [Abstract][Full Text] [Related]
6. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines. Ragupathi G; Cappello S; Yi SS; Canter D; Spassova M; Bornmann WG; Danishefsky SJ; Livingston PO Vaccine; 2002 Jan; 20(7-8):1030-8. PubMed ID: 11803062 [TBL] [Abstract][Full Text] [Related]
7. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361 [TBL] [Abstract][Full Text] [Related]
9. Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine. Ragupathi G; Damani P; Srivastava G; Srivastava O; Sucheck SJ; Ichikawa Y; Livingston PO Cancer Immunol Immunother; 2009 Sep; 58(9):1397-405. PubMed ID: 19190907 [TBL] [Abstract][Full Text] [Related]
10. Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens. Wang ZG; Williams LJ; Zhang XF; Zatorski A; Kudryashov V; Ragupathi G; Spassova M; Bornmann W; Slovin SF; Scher HI; Livingston PO; Lloyd KO; Danishefsky SJ Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2719-24. PubMed ID: 10716997 [TBL] [Abstract][Full Text] [Related]
11. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818 [TBL] [Abstract][Full Text] [Related]
12. Pursuit of optimal carbohydrate-based anticancer vaccines: preparation of a multiantigenic unimolecular glycopeptide containing the Tn, MBr1, and Lewis(y) antigens. Allen JR; Harris CR; Danishefsky SJ J Am Chem Soc; 2001 Mar; 123(9):1890-7. PubMed ID: 11456809 [TBL] [Abstract][Full Text] [Related]
13. Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Slovin SF; Ragupathi G; Adluri S; Ungers G; Terry K; Kim S; Spassova M; Bornmann WG; Fazzari M; Dantis L; Olkiewicz K; Lloyd KO; Livingston PO; Danishefsky SJ; Scher HI Proc Natl Acad Sci U S A; 1999 May; 96(10):5710-5. PubMed ID: 10318949 [TBL] [Abstract][Full Text] [Related]
14. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience. Musselli C; Livingston PO; Ragupathi G J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R20-6. PubMed ID: 11768620 [TBL] [Abstract][Full Text] [Related]
15. From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine. Zhu J; Wan Q; Lee D; Yang G; Spassova MK; Ouerfelli O; Ragupathi G; Damani P; Livingston PO; Danishefsky SJ J Am Chem Soc; 2009 Jul; 131(26):9298-303. PubMed ID: 19518111 [TBL] [Abstract][Full Text] [Related]
16. Synthesis of selected LeY and KH-1 analogues: a medicinal chemistry approach to vaccine optimization. Spassova MK; Bornmann WG; Ragupathi G; Sukenick G; Livingston PO; Danishefsky SJ J Org Chem; 2005 Apr; 70(9):3383-95. PubMed ID: 15844973 [TBL] [Abstract][Full Text] [Related]
17. The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients. Rosenbaum P; Artaud C; Bay S; Ganneau C; Campone M; Delaloge S; Gourmelon C; Loirat D; Medioni J; Pein F; Sablin MP; Tredan O; Varga A; Leclerc C Cancer Immunol Immunother; 2020 May; 69(5):703-716. PubMed ID: 32034426 [TBL] [Abstract][Full Text] [Related]
18. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Sabbatini PJ; Kudryashov V; Ragupathi G; Danishefsky SJ; Livingston PO; Bornmann W; Spassova M; Zatorski A; Spriggs D; Aghajanian C; Soignet S; Peyton M; O'Flaherty C; Curtin J; Lloyd KO Int J Cancer; 2000 Jul; 87(1):79-85. PubMed ID: 10861456 [TBL] [Abstract][Full Text] [Related]
19. Towards a fully synthetic carbohydrate-based anticancer vaccine: synthesis and immunological evaluation of a lipidated glycopeptide containing the tumor-associated tn antigen. Buskas T; Ingale S; Boons GJ Angew Chem Int Ed Engl; 2005 Sep; 44(37):5985-8. PubMed ID: 16108081 [No Abstract] [Full Text] [Related]
20. A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response. Dziadek S; Hobel A; Schmitt E; Kunz H Angew Chem Int Ed Engl; 2005 Nov; 44(46):7630-5. PubMed ID: 16247815 [No Abstract] [Full Text] [Related] [Next] [New Search]